Difference between revisions of "Week4"

From Pheno Wiki
Jump to: navigation, search
Line 4: Line 4:
  
 
*Title
 
*Title
 +
 +
Longitudinal Modeling of Age-Related Memory Decline and the APOE epsilon4 Effect
  
 
*Reference
 
*Reference
Line 36: Line 38:
 
*Abstract
 
*Abstract
  
Background: The APOE4 allele is associated with the risk of late-onset Alzheimer's disease. The age at which memory decline diverges among persons who are homozygous for the APOE4 allele, those who are heterozygous for the allele, and noncarriers is unknown.
+
Background: The APOEepsilon4 allele is associated with the risk of late-onset Alzheimer's disease. The age at which memory decline diverges among persons who are homozygous for the APOEepsilon4 allele, those who are heterozygous for the allele, and noncarriers is unknown.
  
Methods: Using local advertisements, we recruited cognitively normal subjects between the ages of 21 and 97 years, who were grouped according to their APOE4 status. We then followed the subjects with longitudinal neuropsychological testing. Anyone in whom mild cognitive impairment or dementia developed during follow-up was excluded. We compared the rates of decline in predetermined cognitive measures between carriers and noncarriers of the APOE4 allele, using a mixed model for longitudinal change with age.
+
Methods: Using local advertisements, we recruited cognitively normal subjects between the ages of 21 and 97 years, who were grouped according to their APOEepsilon4 status. We then followed the subjects with longitudinal neuropsychological testing. Anyone in whom mild cognitive impairment or dementia developed during follow-up was excluded. We compared the rates of decline in predetermined cognitive measures between carriers and noncarriers of the APOEepsilon4 allele, using a mixed model for longitudinal change with age.
  
Results: We analyzed 815 subjects: 317 APOE4 carriers (79 who were homozygous for the APOE {varepsilon}4 allele and 238 who were heterozygous) and 498 noncarriers. Carriers, as compared with noncarriers, were generally younger (mean age, 58.0 vs. 61.4 years; P<0.001) and were followed for a longer period (5.3 vs. 4.7 years, P=0.01), with an equivalent duration of formal education (15.4 years) and proportion of women (69%). Longitudinal decline in memory in carriers began before the age of 60 years and showed greater acceleration than in noncarriers (P=0.03), with a possible allele–dose effect (P=0.008). We observed similar although weaker effects on measures of visuospatial awareness and general mental status.
+
Results: We analyzed 815 subjects: 317 APOEepsilon4 carriers (79 who were homozygous for the APOEepsilon4 allele and 238 who were heterozygous) and 498 noncarriers. Carriers, as compared with noncarriers, were generally younger (mean age, 58.0 vs. 61.4 years; P<0.001) and were followed for a longer period (5.3 vs. 4.7 years, P=0.01), with an equivalent duration of formal education (15.4 years) and proportion of women (69%). Longitudinal decline in memory in carriers began before the age of 60 years and showed greater acceleration than in noncarriers (P=0.03), with a possible allele–dose effect (P=0.008). We observed similar although weaker effects on measures of visuospatial awareness and general mental status.
  
Conclusions: Age-related memory decline in APOE4 carriers diverges from that of noncarriers before the age of 60 years, despite ongoing normal clinical status.
+
Conclusions: Age-related memory decline in APOEepsilon4 carriers diverges from that of noncarriers before the age of 60 years, despite ongoing normal clinical status.
  
  

Revision as of 18:33, 13 January 2010

Back to NS210b Class page

MANUSCRIPT ID

  • Title

Longitudinal Modeling of Age-Related Memory Decline and the APOE epsilon4 Effect

  • Reference
  • Abstract
  • Keywords
  • Input Author


MANUSCRIPT DETAILS

  • Introduction/Aims
  • Methods
  • Results
  • Summary
  • Discussion


MANUSCRIPT ID

  • Title
  • Reference
  • Abstract

Background: The APOEepsilon4 allele is associated with the risk of late-onset Alzheimer's disease. The age at which memory decline diverges among persons who are homozygous for the APOEepsilon4 allele, those who are heterozygous for the allele, and noncarriers is unknown.

Methods: Using local advertisements, we recruited cognitively normal subjects between the ages of 21 and 97 years, who were grouped according to their APOEepsilon4 status. We then followed the subjects with longitudinal neuropsychological testing. Anyone in whom mild cognitive impairment or dementia developed during follow-up was excluded. We compared the rates of decline in predetermined cognitive measures between carriers and noncarriers of the APOEepsilon4 allele, using a mixed model for longitudinal change with age.

Results: We analyzed 815 subjects: 317 APOEepsilon4 carriers (79 who were homozygous for the APOEepsilon4 allele and 238 who were heterozygous) and 498 noncarriers. Carriers, as compared with noncarriers, were generally younger (mean age, 58.0 vs. 61.4 years; P<0.001) and were followed for a longer period (5.3 vs. 4.7 years, P=0.01), with an equivalent duration of formal education (15.4 years) and proportion of women (69%). Longitudinal decline in memory in carriers began before the age of 60 years and showed greater acceleration than in noncarriers (P=0.03), with a possible allele–dose effect (P=0.008). We observed similar although weaker effects on measures of visuospatial awareness and general mental status.

Conclusions: Age-related memory decline in APOEepsilon4 carriers diverges from that of noncarriers before the age of 60 years, despite ongoing normal clinical status.


  • Keywords

memory decline, APOE4, memory disorders, longitudinal neuropsychological testing


  • Input Author

Kelley O'Donnell


MANUSCRIPT DETAILS

  • Introduction/Aims
  • Methods
  • Results
  • Summary
  • Discussion


INFORMATICS: GenBank

GenBank is an open-access database of annotated sequences of DNA, mRNA, and the corresponding proteins. One can add [1] to the database, submitting sequences, further annotations, and corrections. Alternatively (and likely more usefully), one can search GenBank. Searches are conducted via Entrez Nucleotide [2].